Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
Рядок 1: Рядок 1:
−
In line with D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular techniques are made use of to look for residual illness. These sufferers are regarded as to have accomplished a minimal residual disease (MRD) damaging status.17-20 Several phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than people that remain MRD positive, and this really is true for individuals treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that individuals acquiring MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Regrettably, however, a few of these research had been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are numerous caveats to the use of MRD analysis in patients with CLL.28 First, CLL remains incurable and a minimum of 30  of sufferers who achieve MRD negativity following front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a disease relapse within 5 years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response in comparison with treatment at the time of clinical relapse. In reality, extremely few studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and some from the tactics tested, while powerful, resulted in considerable toxicity.33-35 Thirdly, it may very well be argued that MRD assessment is merely a surrogate for evalution of other adverse prognostic markers considering the fact that, for example, sufferers with a 17p014 Ferrata Storti Foundation. This really is an open-access paper. doi:10.3324/haematol.2013.099796 The on-line version of this article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive immediately after therapy when compared with sufferers without the need of this chromosome abnormality.18 For all these factors, current suggestions for the management of sufferers with CLL propose MRD assessment only within clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the effect of MRD around the outcome of individuals with CLL receiving any front-line therapy in the context of an incredibly detailed prognostic evaluation, which includes lately described recurrent gene mutations.survival and general survival had been calculated employing a landmark analysis. All calculations were performed [http://mainearms.com/members/nerveguide65/activity/1671141/ Rom the food supply. Sources of preformed vitamin D] utilizing either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been considered statistically substantial. A detailed explanation in the statistical approaches is obtainable inside the On the internet Supplement.Benefits Baseline characteristicsThe median age with the whole cohort was 58 years (range, 27-93 years), along with the percentage of individuals older than 70 years was 22 .
+
doi:ten.3324/haematol.2013.099796 The on-line [http://sciencecasenet.org/members/era1march/activity/663131/ Dine deficiency, a selenium deficiency, or high intake of goitrogens] version of this short article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013.Le illness in peripheral blood or bone marrow even when pretty sensitive immunophenotypic or molecular methods are applied to appear for residual illness. These individuals are considered to have achieved a minimal residual illness (MRD) unfavorable status.17-20 Quite a few phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than individuals who stay MRD optimistic, and that is correct for individuals treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Furthermore, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that patients acquiring MRD negativity had drastically longer progression-free and all round survivals, irrespectively from the treatment received.18 Sadly, having said that, a few of these studies had been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from therapy initiation.27 In addition, there are many caveats to the use of MRD analysis in patients with CLL.28 Initially, CLL remains incurable and at least 30  of sufferers who realize MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC ultimately practical experience a illness relapse inside 5 years.18 Secondly, unlike the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity soon after an initial MRD-negative response compared to treatment in the time of clinical relapse. Actually, very handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the tactics tested, though effective, resulted in considerable toxicity.33-35 Thirdly, it may be argued that MRD assessment is simply a surrogate for evalution of other adverse prognostic markers due to the fact, for instance, sufferers using a 17p014 Ferrata Storti Foundation. This really is an open-access paper. doi:10.3324/haematol.2013.099796 The online version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a higher probability of remaining MRD-positive soon after therapy in comparison with individuals devoid of this chromosome abnormality.18 For all these motives, current recommendations for the management of individuals with CLL advocate MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the effect of MRD on the outcome of individuals with CLL getting any front-line therapy inside the context of an extremely detailed prognostic evaluation, including recently described recurrent gene mutations.survival and general survival were calculated making use of a landmark analysis. All calculations have been performed using either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 have been thought of statistically substantial. A detailed explanation from the statistical strategies is accessible inside the On line Supplement.Benefits Baseline characteristicsThe median age on the entire cohort was 58 years (range, 27-93 years), along with the percentage of patients older than 70 years was 22 .

Версія за 22:22, 9 лютого 2018

doi:ten.3324/haematol.2013.099796 The on-line Dine deficiency, a selenium deficiency, or high intake of goitrogens version of this short article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013.Le illness in peripheral blood or bone marrow even when pretty sensitive immunophenotypic or molecular methods are applied to appear for residual illness. These individuals are considered to have achieved a minimal residual illness (MRD) unfavorable status.17-20 Quite a few phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than individuals who stay MRD optimistic, and that is correct for individuals treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Furthermore, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that patients acquiring MRD negativity had drastically longer progression-free and all round survivals, irrespectively from the treatment received.18 Sadly, having said that, a few of these studies had been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from therapy initiation.27 In addition, there are many caveats to the use of MRD analysis in patients with CLL.28 Initially, CLL remains incurable and at least 30 of sufferers who realize MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC ultimately practical experience a illness relapse inside 5 years.18 Secondly, unlike the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity soon after an initial MRD-negative response compared to treatment in the time of clinical relapse. Actually, very handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the tactics tested, though effective, resulted in considerable toxicity.33-35 Thirdly, it may be argued that MRD assessment is simply a surrogate for evalution of other adverse prognostic markers due to the fact, for instance, sufferers using a 17p014 Ferrata Storti Foundation. This really is an open-access paper. doi:10.3324/haematol.2013.099796 The online version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a higher probability of remaining MRD-positive soon after therapy in comparison with individuals devoid of this chromosome abnormality.18 For all these motives, current recommendations for the management of individuals with CLL advocate MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the effect of MRD on the outcome of individuals with CLL getting any front-line therapy inside the context of an extremely detailed prognostic evaluation, including recently described recurrent gene mutations.survival and general survival were calculated making use of a landmark analysis. All calculations have been performed using either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 have been thought of statistically substantial. A detailed explanation from the statistical strategies is accessible inside the On line Supplement.Benefits Baseline characteristicsThe median age on the entire cohort was 58 years (range, 27-93 years), along with the percentage of patients older than 70 years was 22 .

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Le_disease_in_peripheral_blood_or_bone_marrow_even_when&oldid=286146